Foundayo

Patient

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

Safety: Foundayo carries a boxed warning for possible thyroid C-cell tumors. It did not activate ordinary rat or mouse GLP-1 receptors or produce tumors in the cited rodent studies; human relevance of the class finding is unknown. Formal contraindications are personal or family medullary thyroid carcinoma, MEN2, and prior serious hypersensitivity to orforglipron or an excipient. Foundayo US Prescribing Information (DailyMed), Boxed Warning and §4.

patient-01 — Do I have to take Foundayo on an empty stomach like Rybelsus?

Established. No. The Foundayo label says the tablet is taken once each day with or without food. It also says to swallow it whole. Rybelsus needs an empty stomach, no more than 4 ounces of water, and a 30-minute wait before food, drinks, or other pills. Do not copy the routine from one product to the other. Foundayo acts on GLP-1 receptors that help control hunger. A pharmacist can review the bottle and your full routine with you.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,12.1; Rybelsus and Ozempic tablets US Prescribing Information, §2.1.

patient-02 — Who can use Foundayo for weight loss?

Established. The US label says adults with obesity may use Foundayo. Adults who are overweight may also qualify if they have at least one health problem tied to weight. It is used with changes in food and activity. The label does not say it is right for everyone who wants to lose weight. A prescriber checks health history, other drugs, and key risks first. The drug acts on GLP-1 receptors in the body to help lower food intake.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,4,12.1.

patient-03 — How much weight did people lose in a trial?

Established. In a 72-week study of adults without diabetes, the group assigned a research capsule matched to today’s 17.2 mg tablet lost 11.1% of starting body weight on average. The placebo group lost 2.1%. That is a group result; one person may lose more, less, or no weight. Food, activity, side effects, and treatment changes also matter. A receptor picture cannot predict your own outcome. Ask the care team how they will track progress with you.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§14; ATTAIN-1, PMID 40960239.

patient-04 — What side effects might I notice?

Established. The label lists nausea, hard stools, loose stools, vomiting, upset stomach, belly pain, and hair loss. Nausea does not prove the drug works. In trials, 4% to 5% of treated people had hair loss, versus 2% on placebo. Tell your care team if you cannot drink or keep food down. Strong belly pain that will not stop needs prompt care. It may be a sign of a serious problem with the pancreas.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.2,5.4,6.1.

patient-05 — What does the thyroid warning mean for me?

Established. Foundayo has a boxed warning about a possible risk of thyroid C-cell tumors. This drug did not cause tumors in the rodent studies in the label, and it does not activate ordinary mouse or rat GLP-1 receptors. The meaning of the class finding for people is unknown. The label says people with a personal or family history of medullary thyroid cancer, or MEN2, must not use it. Tell the prescriber about that history or a neck lump.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§Boxed Warning,4,5.1,13.1.

patient-06 — Can low blood sugar happen if I do not have diabetes?

Established. Yes. The label tells all patients about low blood sugar. It can happen in people without type 2 diabetes, and the risk goes up when insulin or a drug that makes the body release insulin is also used. Signs may include shaking, sweating, hunger, or confusion. Ask the care team what signs to watch for and what to do if they occur. Do not change any other medicine based only on this page.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.5,6.1.

patient-07 — What if I miss tablets?

Established. The label has different instructions for one missed tablet and for seven or more missed days in a row. It says a single missed dose is taken as soon as possible, but two tablets should not be taken on the same day. After seven or more days, the label calls for restarting a lower step of the dose plan. The right restart step depends on the person and the prior dose. Ask the pharmacist or prescriber to guide that plan.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.3.

patient-08 — Does Foundayo change birth control or pregnancy plans?

Established. Foundayo may make birth control pills work less well when you start it or raise the dose. The label calls for birth control that is not a pill, or an added barrier method, for 30 days after the start and after each dose increase. The label also warns of possible harm in pregnancy. Weight loss does not help a baby during pregnancy. Foundayo is not recommended while nursing. Tell your care team about plans for pregnancy or a missed period, and ask what birth control plan fits you.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§7.3,8.1–8.3.

Caregiver

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

caregiver-01 — She started a new dose and uses the pill for birth control. What changes?

Established. The label says oral birth control pills may work less well during Foundayo dose changes. It calls for a non-oral method or an added barrier method for 30 days after starting Foundayo and for 30 days after each dose increase. Help record the date of each dose step and bring the birth control name to the pharmacist. Do not choose or stop a method for her. A prescriber can help make a plan that fits her.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,7.3.

caregiver-02 — What should I watch and write down after a dose change?

Established. Watch for nausea, vomiting, loose stools, belly pain, dizziness, and trouble drinking. Write down the dose-step date, fluid intake if it is poor, and symptoms that last. The label raises the dose only after at least 30 days at each step, based on response and tolerance. A care team can use the log to assess side effects and weight change. Severe belly pain, swelling with breathing trouble, or signs of dehydration need prompt help.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,5.2–5.6.

caregiver-03 — When might stomach symptoms become a kidney problem?

Established. Vomiting and diarrhea can drain body fluid. The Foundayo label warns that this can lead to kidney injury. Watch for ongoing fluid loss, dark urine, dizziness, or trouble drinking, and contact the care team. Record when symptoms began and the other drugs the person takes. The prescriber may need to check kidney function. Do not guess about stopping or restarting treatment; ask for a plan for the person you help.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.3,5.4.

caregiver-04 — Which symptoms call for urgent care?

Established. Strong belly pain that will not stop needs prompt assessment because pancreatitis is a warning. Swelling of the face, lips, tongue, or throat, or trouble breathing, can mean a serious allergy and needs emergency help. Repeated vomiting with little fluid can also become urgent. Keep a list of medicines and the last Foundayo dose ready for the care team. These signs need an assessment; they do not prove one cause by themselves.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.2,5.4,5.6.

caregiver-05 — How can I help with the once-daily routine?

Established. The label describes one whole tablet each day, with or without food, and no more than one tablet in a day. A simple calendar can show the usual time and each planned dose step. The label spaces dose increases by at least 30 days. If a week or more is missed, a lower restart step may be needed. Let the pharmacist or prescriber set that step; avoid filling in gaps by giving extra tablets.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,2.3.

caregiver-06 — What other medicines should I bring to a review?

Established. Bring a full list of pills, shots, and other drugs. Include birth control pills, a cholesterol drug such as simvastatin, insulin, and drugs that make the body release insulin. Some drugs can change how Foundayo works, and Foundayo can affect other drugs. The label also advises against taking another GLP-1 drug at the same time. A pharmacist can check the exact names and doses on the bottles. A broad drug type alone may not be enough.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,5.5,7.1–7.3.

caregiver-07 — Should I worry about low blood sugar?

Established. Yes. Foundayo can lower blood sugar even when it is used for weight control. The risk is higher if the person also uses insulin or a drug that makes the body release insulin. Ask the care team which signs to watch for, what low means for this person, and what plan to follow. Note shaking, sweat, or odd confusion, along with meals and the medicine list. Do not change another drug without the prescriber.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.5,6.1.

caregiver-08 — What should I mention before a procedure?

Established. Tell the team before a test or surgery that the person takes Foundayo. This drug can slow the way food leaves the stomach. The label reports food or fluid entering the lungs during deep sedation or full anesthesia with GLP-1 drugs. It gives no single rule for when to hold a dose that removes all risk. Share the dose, any nausea or vomiting, and the planned test. The care team will assess the risk and give a plan.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.9,12.2.

Pharmacist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

Safety: Foundayo carries a boxed warning for possible thyroid C-cell tumors. It did not activate ordinary rat or mouse GLP-1 receptors or produce tumors in the cited rodent studies; human relevance of the class finding is unknown. Formal contraindications are personal or family medullary thyroid carcinoma, MEN2, and prior serious hypersensitivity to orforglipron or an excipient. Foundayo US Prescribing Information (DailyMed), Boxed Warning and §4.

pharmacist-01 — A patient on clarithromycin asks about the Foundayo maximum. What does the label say?

Established. Clarithromycin is a strong CYP3A4 inhibitor; the Foundayo label caps the dose at 9 mg once daily with a strong CYP3A4 inhibitor. First review the full regimen and confirm the inhibitor, current Foundayo strength, and treatment duration. The label separately says to avoid strong CYP3A4 inhibitors that also inhibit OATP1B, such as ritonavir. Do not turn a general inhibitor cap into permission for that combined interaction. The prescriber should resolve any change.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.2,7.1,12.3.

pharmacist-02 — How should the food rule be explained alongside oral semaglutide?

Established. Foundayo is taken once daily with or without food and swallowed whole. That is a product-specific instruction. Oral semaglutide tablets have fasting and water restrictions, so using the old semaglutide routine as a class rule creates confusion. Confirm the exact product and formulation before counseling. Foundayo oral bioavailability is about 77% at 0.8 mg in the label; this number does not establish comparative efficacy or interchangeability with semaglutide.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,12.3; Rybelsus and Ozempic tablets US Prescribing Information, §2.1.

pharmacist-03 — What is the simvastatin action point?

Established. The label reports simvastatin acid exposure about 2 to 2.5 times higher with Foundayo and limits simvastatin to 20 mg daily during concomitant use. Check the exact statin, dose, and other interaction risks rather than extrapolating the limit to every statin. Rosuvastatin exposure also increased, but by a different amount. A pharmacist can flag the label limit and potential muscle adverse effects to the prescriber; the patient should not independently change either drug.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§7.2,12.3.

pharmacist-04 — How do strong CYP3A4 inducers change the review?

Established. The label says to avoid concomitant strong CYP3A4 inducers. In its interaction study, carbamazepine lowered orforglipron AUC by 82% and peak concentration by 55%. That large exposure change may undermine the expected effect. Reconcile prescription and nonprescription products, identify the specific inducer, and contact the prescriber about an alternative. The interaction data do not support simply increasing Foundayo beyond its labeled range to compensate.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§7.1,12.3.

pharmacist-05 — What contraceptive counseling is specific to this product?

Established. Foundayo delays gastric emptying and may reduce oral hormonal contraceptive effectiveness during initiation and escalation. The label calls for a non-oral contraceptive or an added barrier method for 30 days after starting and after each dose increase. Check whether the patient uses an oral product, document the dose-step date, and direct method selection to the prescribing team. The rule applies again after each escalation; it is not a one-time warning only at the first tablet.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§7.3,12.2.

pharmacist-06 — What does the label say about missed doses and restarting?

Established. For one missed dose, the label says to take it as soon as possible and not more than one tablet on the same day. For at least seven consecutive missed doses, it calls for reinitiating escalation at a lower dose. The exact lower step depends on the prior regimen and should be determined with the prescriber. Ask about the date of the last dose, strength, symptoms, and other drugs before counseling. Avoid a catch-up double dose.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.3.

pharmacist-07 — Which patients need an added safety screen?

Established. Screen for personal or family medullary thyroid carcinoma or MEN2 and serious hypersensitivity, the formal contraindications. The label also does not recommend Foundayo for severe gastroparesis or severe hepatic impairment, Child-Pugh C. Review pancreatitis, gallbladder, kidney-volume, and hypoglycemia risks, particularly with insulin or a secretagogue. These distinctions matter: a warning or nonrecommendation is not identical to a contraindication. Route uncertain histories to the prescriber.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§4,5.1–5.8,8.6.

pharmacist-08 — Can Foundayo be combined with another GLP-1 drug?

Established. The indication section says concomitant use with another GLP-1 receptor agonist is not recommended. A medication history should include injectable and oral products, because a patient may not recognize two brand names as members of the same class. Confirm whether a prior prescription is still active before dispensing or providing a switching plan. The label does not make tablet and capsule strengths interchangeable; clinical trial capsule doses should not be translated into retail tablet instructions.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,3,14.

Clinician

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

Safety: Foundayo carries a boxed warning for possible thyroid C-cell tumors. It did not activate ordinary rat or mouse GLP-1 receptors or produce tumors in the cited rodent studies; human relevance of the class finding is unknown. Formal contraindications are personal or family medullary thyroid carcinoma, MEN2, and prior serious hypersensitivity to orforglipron or an excipient. Foundayo US Prescribing Information (DailyMed), Boxed Warning and §4.

clinician-01 — What weight loss should I quote at the 17.2 mg tablet dose?

Established. In label Trial 1, 3,127 adults without diabetes were randomized. At 72 weeks, mean body-weight change under the treatment-regimen estimand was −11.1% with the 17.2 mg tablet-equivalent research capsule dose versus −2.1% with placebo, a 9.0-percentage-point difference. The proportion losing at least 10% was 54.5% versus 13%. Trial estimates are group averages, not individual forecasts. The published paper reports the same capsule trial with its own rounding; retain each source’s figures separately.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§14; ATTAIN-1, PMID 40960239.

clinician-02 — What is known in people with type 2 diabetes?

Established. Label Trial 2 included 1,613 adults with type 2 diabetes and obesity or overweight. At 72 weeks, the 17.2 mg tablet-equivalent capsule arm had mean weight change of −9.6% versus −2.5% with placebo; HbA1c changed −1.7 versus −0.4 percentage points. Separate ACHIEVE-1 diabetes results showed HbA1c lowering, but the checked US Foundayo indication is adult weight management. Trial enrollment is not an additional labeled treatment indication. Review current labeling before conveying scope.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,14; ATTAIN-2, PMID 41275875; ACHIEVE-1, PMID 40544435.

clinician-03 — Does the cardiovascular study establish a benefit indication?

Established. ACHIEVE-4 compared orforglipron with insulin glargine in type 2 diabetes. The reported MACE-4 rates were 4.2% versus 5.0%, hazard ratio 0.84 with 95% confidence interval 0.59–1.20. It supported a cardiovascular safety noninferiority conclusion, not superiority. The July 2026 Foundayo label is for adult weight management and does not claim cardiovascular outcome reduction. Keep the trial population, comparator, endpoint, and regulatory claim distinct when discussing benefit.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1; ACHIEVE-4, PMID 42815506.

clinician-04 — Which interactions could change the benefit-risk assessment?

Established. Strong CYP3A4 inhibitors cap Foundayo at 9 mg daily, but strong inhibitors that also inhibit OATP1B should be avoided. Strong CYP3A4 inducers should also be avoided; carbamazepine lowered AUC 82% in a study. Simvastatin is limited to 20 mg daily during coadministration. Oral hormonal contraception needs a non-oral or added barrier method for 30 days after start and each escalation. These are product-specific label actions, not class assumptions.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.2,7.1–7.3,12.3.

clinician-05 — Which histories change eligibility or monitoring?

Established. Personal or family medullary thyroid carcinoma, MEN2, and serious hypersensitivity are formal contraindications. Severe gastroparesis and severe hepatic impairment, Child-Pugh C, are not-recommended settings. Pancreatitis, gallbladder disease, volume depletion with kidney injury, and hypoglycemia require attention. In patients with type 2 diabetes and a history of retinopathy, the label says to monitor for progression. Sort each finding by its actual label category before making an individual decision.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§4,5.1–5.8,8.6.

clinician-06 — How does dose escalation relate to tolerability?

Established. The tablet label starts at 0.8 mg daily, then describes 2.5 and 5.5 mg after at least 30 days at each prior step. Later increases to 9, 14.5, or 17.2 mg also require at least 30 days on the current dose, based on response and tolerability. Gastrointestinal adverse effects are common, and prolonged vomiting may cause volume depletion and kidney injury. This is the labeled schedule, not a personalized escalation order for any patient.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,5.3,5.4,6.1.

clinician-07 — How should aspiration risk be discussed before sedation?

Established. Foundayo delays gastric emptying, although the effect diminishes with time. The label reports pulmonary aspiration with GLP-1 receptor agonists during general anesthesia or deep sedation and instructs patients to disclose use before procedures. It does not establish that a fixed holding interval prevents aspiration. Assess symptoms, timing, procedure, and current guidance with the anesthesia team. Avoid turning the gastric-emptying mechanism into a universal rule to stop therapy.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.9,12.2.

clinician-08 — Can an indirect comparison rank it against oral semaglutide?

Uncertain. No head-to-head obesity randomized trial against oral semaglutide is identified in the sources reviewed for this draft. Different trials may vary in eligibility, background care, follow-up, estimands, and missing-data handling. ATTAIN-1 label Trial 1 gives −11.1% versus −2.1% at 72 weeks for the 17.2 mg tablet-equivalent research capsule dose, but that within-trial contrast cannot rank another product. A competitor-sponsored indirect analysis is hypothesis-generating. Review direct comparative outcomes before asserting superiority or fewer adverse effects.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§14; ATTAIN-1, PMID 40960239; Novo Nordisk ORION indirect-comparison announcement, April 2, 2026.

Nurse

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

Safety: Foundayo carries a boxed warning for possible thyroid C-cell tumors. It did not activate ordinary rat or mouse GLP-1 receptors or produce tumors in the cited rodent studies; human relevance of the class finding is unknown. Formal contraindications are personal or family medullary thyroid carcinoma, MEN2, and prior serious hypersensitivity to orforglipron or an excipient. Foundayo US Prescribing Information (DailyMed), Boxed Warning and §4.

nurse-01 — How often can the Foundayo dose go up?

Established. The label spaces each step by at least 30 days on the current tablet strength. It starts at 0.8 mg, then lists 2.5 mg and 5.5 mg; later options are 9, 14.5, and 17.2 mg based on response and tolerance. Teach back the date of the next planned step rather than assuming a monthly change will happen. Ask about nausea, vomiting, fluid intake, and other medicines before the care team confirms any increase.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,5.3,5.4.

nurse-02 — What administration points should teach-back cover?

Established. Ask the patient to explain the product name, the once-daily routine, and how the tablet is swallowed whole. The label allows Foundayo with or without food and says not to take more than one tablet in a day. This differs from fasting instructions for some other oral GLP-1 products. Have the patient show the prescribed strength on the container and name whom they would call after several missed days. Avoid choosing a restart strength in a general lesson.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,2.3.

nurse-03 — What should be assessed during vomiting or diarrhea?

Established. Record how long symptoms have lasted, whether fluids stay down, dizziness, urine changes, weight trend, and the other medicines being used. Foundayo can cause gastrointestinal effects; fluid loss can lead to acute kidney injury. The label asks for renal-function monitoring when adverse effects could cause volume depletion. Severe, persistent belly pain also raises concern for pancreatitis. Escalate to the clinical team for assessment and an individual plan rather than assuming every symptom is routine.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.2–5.4.

nurse-04 — When is glucose monitoring especially relevant?

Established. Foundayo acts through the GLP-1 receptor and can lower blood sugar. The label alerts all patients to hypoglycemia, with higher risk when insulin or an insulin secretagogue is used. Check the medication list, ask about sweating, shaking, hunger, or confusion, and follow the care plan for glucose checks. Do not assume weight-management use means glucose effects are absent. Any adjustment of insulin or a secretagogue belongs to the prescribing team.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.5,7.2,12.1.

nurse-05 — What should a patient report before anesthesia?

Established. Teach the patient to tell the procedure and anesthesia teams that they take Foundayo, including the current dose and recent stomach symptoms. GLP-1 receptor agonists can delay stomach emptying. The label describes aspiration during general anesthesia and deep sedation, even when patients followed fasting instructions. It does not give a universal safe holding interval. The procedural team will assess aspiration risk and give instructions for that specific procedure.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.9,12.2.

nurse-06 — How should contraception teach-back be framed?

Established. Ask whether the patient uses a birth control pill and whether a Foundayo dose step is planned. The label calls for a non-oral method or an added barrier method for 30 days after Foundayo starts and for 30 days after each escalation. Have the patient repeat the timing in their own words and refer method selection to the prescriber or pharmacist. Record the escalation date; do not assume the first 30 days cover later increases.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§7.3.

nurse-07 — Which risks need immediate escalation?

Established. The formal contraindications are personal or family medullary thyroid carcinoma, MEN2, and serious hypersensitivity to Foundayo ingredients. During treatment, persistent severe belly pain, facial or throat swelling, breathing trouble, or major fluid loss needs prompt assessment. The label also warns about gallbladder disease. A nurse should document the symptom, onset, dose history, and vital signs, then follow local escalation protocols. A warning sign does not by itself establish a diagnosis.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§4,5.1–5.8.

nurse-08 — Can pulse change during treatment?

Established. The label reports an average heart-rate increase of 4 to 5 beats per minute from baseline, versus 0.5 beat per minute with placebo. That group average is not a prediction for each patient. Record pulse with the broader assessment, including symptoms and other causes of a change. Foundayo also reduces weight and food intake through GLP-1 receptor signaling. Bring persistent or symptomatic pulse changes to the prescribing team rather than using this average as a personal safety threshold.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§6.1,12.1.

Student

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

student-01 — Why is a rodent-negative drug still boxed for thyroid C-cell tumors?

Established. Orforglipron activates human GLP-1 receptors but is not pharmacologically active at ordinary rat or mouse receptors. It did not produce tumors in the rodent studies described in the label. Other GLP-1 agonists that are rodent-active produced C-cell tumors, and the relevance of that class finding to people remains unknown. Foundayo therefore retains the boxed warning and the medullary thyroid carcinoma or MEN2 contraindication. Species-selective receptor pharmacology explains the evidence difference, not an exemption from the warning.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§Boxed Warning,4,5.1,13.1; Kawai et al., PMID 33177239.

student-02 — How can a small molecule activate a peptide receptor?

Established. The human GLP-1 receptor is a class B G-protein-coupled receptor. Cryo-EM structure 6XOX places LY3502970, orforglipron, high in its transmembrane pocket under an extracellular-domain Trp33 lid. Receptor activation engages Gs, adenylyl cyclase, and cAMP signaling. The human receptor response can alter appetite-related circuits and food intake, leading to measured weight loss in trials. The structure shows a binding pose; it does not by itself predict an individual clinical response.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1,14; Kawai et al., PMID 33177239; RCSB PDB 6XOX.

student-03 — What does partial Gs agonism mean here?

Probable. In receptor assays, orforglipron produced a smaller maximal Gs-linked response than a reference full agonist and little beta-arrestin recruitment. These are assay-dependent descriptions of signaling, not proof of better human safety. GLP-1 receptor activation changes cAMP in responsive cells and is associated with lower food intake. To test whether this signaling profile changes tolerability, one would need suitable human comparative evidence, not only a cell assay or a structure.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1; Sloop et al., PMID 39693407.

student-04 — Why is Foundayo taken with or without food?

Established. Orforglipron is an orally active nonpeptide small molecule. The label reports absolute bioavailability of 77% at 0.8 mg and peak concentration at 4 to 8 hours, and it permits once-daily use with or without food. This is a product-specific instruction. Rybelsus is a peptide formulation with different absorption requirements. Do not generalize an older approximate 1% figure to every current oral semaglutide product or treat bioavailability as a direct efficacy ranking.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,12.3; Rybelsus and Ozempic tablets US Prescribing Information, §2.1.

student-05 — What causes the main gastrointestinal warnings?

Established. GLP-1 receptor signaling slows stomach emptying, especially early in treatment, and affects appetite pathways. Nausea, vomiting, constipation, and diarrhea were common in Foundayo trials. The gastric effect diminishes over time; nausea is an adverse event, not evidence that weight loss will occur. Persistent vomiting can cause volume loss and kidney injury, while severe abdominal pain raises concern for pancreatitis. The symptom pattern requires clinical assessment; the receptor mechanism alone cannot identify the cause.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.2–5.4,6.1,12.1,12.2.

student-06 — How does the body handle orforglipron?

Established. The label reports a half-life of about 29 to 49 hours, peak concentration at 4 to 8 hours, and steady state in about one week. Oxidative metabolism is mainly through CYP3A4; in vitro work also identifies CYP2J2 substrate activity. About 87% of a studied dose was recovered in feces as metabolites. That handling explains why strong enzyme inhibitors and inducers are clinically important. It does not justify a student calculating a personal dose from the half-life.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§7.1,12.3.

student-07 — Why do tablet and trial capsule numbers differ?

Established. Published ATTAIN studies used development capsules, whereas the marketed US Foundayo label lists tablet strengths from 0.8 to 17.2 mg. The label reports outcomes by tablet-equivalent dose. A number such as a 36 mg study capsule is not a retail tablet instruction and should not be read as a greater permitted tablet dose. Compare the formulation, estimand, population, and endpoint before reconciling trial figures. The approved maximum tablet dose is 17.2 mg once daily.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,3,14; ATTAIN-1, PMID 40960239.

student-08 — Does glucose lowering mean a diabetes indication?

Established. GLP-1 receptor signaling can stimulate glucose-dependent insulin release and affect glucagon. Trials in type 2 diabetes measured HbA1c lowering. Yet the checked July 2026 US Foundayo indication is adult weight reduction and maintenance with diet and activity, not treatment of diabetes as such. This is a useful distinction between pharmacodynamic effect, trial result, and approved indication. The label still warns about low blood sugar, particularly with insulin or a secretagogue.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,5.5,12.1,14; ACHIEVE-1, PMID 40544435.

Scientist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

scientist-01 — What does low intrinsic efficacy with little beta-arrestin recruitment establish?

Probable. Sloop and colleagues report high-affinity human GLP-1R binding and low intrinsic efficacy in Gs-linked assays with negligible beta-arrestin recruitment under their test conditions. Those observations define an assay phenotype and suggest testable signaling hypotheses. They do not demonstrate lower nausea rates or better weight loss than another GLP-1 agonist. Human clinical endpoints require suitably controlled comparisons. Specify the assay system, receptor expression, reference agonist, and endpoint before treating bias as a drug-wide constant.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1; Sloop et al., PMID 39693407.

scientist-02 — What supports direct engagement of human GLP-1R?

Established. Kawai and colleagues resolved a cryo-EM complex of human GLP-1R, Gs, and LY3502970, deposited as PDB 6XOX. Sloop and colleagues reported receptor binding and functional G-protein signaling. Together, structure and cell assays support direct engagement, while the label describes effects on appetite and human weight outcomes. A static structure is one receptor conformation, and engineered cell systems do not recapitulate every human tissue. The clinical trial is a separate evidence layer for the outcome.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1,14; Kawai et al., PMID 33177239; Sloop et al., PMID 39693407; RCSB PDB 6XOX.

scientist-03 — What is the evidence for species selectivity?

Established. The extracellular-domain Trp33 contact in the human receptor is replaced by serine in ordinary rat and mouse GLP-1R. Kawai and colleagues connected that residue to species-selective activation, and Sloop and colleagues used modified rodent receptor systems to study pharmacology. The label states that orforglipron is inactive in ordinary rats and mice. Therefore, responses in engineered animals should be identified as such. Species selectivity explains why rodent findings differ, but it cannot settle human long-term thyroid risk.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§Boxed Warning,13.1; Kawai et al., PMID 33177239; Sloop et al., PMID 39693407.

scientist-04 — What do the trials establish about weight?

Established. The Foundayo label reports randomized Trial 1 with 3,127 adults without type 2 diabetes over 72 weeks. Mean weight change at the 17.2 mg tablet-equivalent capsule dose was −11.1% versus −2.1% with placebo under the label analysis. Trial 2 included 1,613 adults with type 2 diabetes and reported −9.6% versus −2.5%. These within-trial contrasts establish efficacy in their studied populations and regimens. They do not isolate the contribution of one neural circuit or support cross-trial superiority claims.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§14; ATTAIN-1, PMID 40960239; ATTAIN-2, PMID 41275875.

scientist-05 — Are animal appetite circuits mapped directly in humans?

Uncertain. The label describes brain distribution and activation of appetite-related neurons in animal experiments. Human weight and food-intake outcomes support a clinical effect, but do not identify every human neuronal population engaged by the drug. A cAMP assay establishes receptor signaling under laboratory conditions, not a complete causal map from receptor to eating behavior. Studies using human-relevant imaging or perturbation could narrow that gap. Present detailed neuronal localization as nonclinical evidence, not a direct human observation.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1,12.2,14; Sloop et al., PMID 39693407.

scientist-06 — Can indirect obesity comparisons resolve relative tolerability?

Uncertain. No. An indirect comparison across separate orforglipron and oral semaglutide trials can generate a hypothesis, but differences in populations, titration, estimands, ascertainment, and missing-data methods can distort the contrast. ORION was a competitor-sponsored indirect analysis. The receptor bias observed by Sloop does not independently validate an adverse-event advantage. A randomized head-to-head comparison with prespecified efficacy and tolerability endpoints would be stronger evidence. Keep the sponsor and method beside any indirect estimate.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§14; ATTAIN-1, PMID 40960239; Sloop et al., PMID 39693407; Novo Nordisk ORION indirect-comparison announcement, April 2, 2026; Novo Nordisk ORION indirect-comparison announcement, April 2, 2026.

scientist-07 — How much can the rodent cancer study exclude?

Established. The label reports that orforglipron was inactive at ordinary rodent GLP-1 receptors and did not produce tumors in its described rodent studies. This is a molecule-specific negative finding under those study conditions. Other GLP-1 agonists have produced rodent C-cell tumors, and the human relevance of that class finding is unknown. Absence of tumors in an inactive species does not establish absence of human risk. That is why the boxed warning and MTC/MEN2 contraindication remain.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§Boxed Warning,4,5.1,13.1.

scientist-08 — Which exposure measures would matter in comparative work?

Probable. The Foundayo label gives 77% absolute bioavailability at 0.8 mg, a 4–8 hour time to peak, and a 29–49 hour half-life. These are useful for exposure and interaction hypotheses, especially CYP3A4 effects. They cannot be used alone to compare clinical potency with a peptide GLP-1 drug. A rigorous comparison would align formulation, administered dose, exposure-response, population, and endpoint. The label also reports gastric-emptying effects that diminish with time, complicating simple absorption stories.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.2,12.3.

Chemist

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

chemist-01 — Which residue makes orforglipron primate-selective?

Established. Kawai and colleagues identify Trp33 in the extracellular domain of the human GLP-1 receptor as a lid over the LY3502970 binding site. Ordinary rodent receptors have Ser33 instead and are not activated by orforglipron in the same way. The 6XOX cryo-EM structure supports the contact geometry; receptor substitution experiments strengthen the functional interpretation. This is a receptor-side selectivity determinant, not a claim that one atom alone controls every pharmacologic property or clinical outcome.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1,13.1; Kawai et al., PMID 33177239; RCSB PDB 6XOX.

chemist-02 — What does PDB 6XOX show about binding?

Established. PDB 6XOX shows LY3502970 bound to human GLP-1R in a Gs complex at about 3.1 Å resolution. The ligand occupies an upper transmembrane pocket, contacts the extracellular domain and ECL2, and has a reported hydrogen bond to Lys197. Its pose differs from a peptide ligand spanning the extracellular receptor surface. A cryo-EM pose is a structural model under experimental conditions; it does not directly measure oral absorption, clinical selectivity, or comparative weight loss.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1; Kawai et al., PMID 33177239; RCSB PDB 6XOX.

chemist-03 — What is the marketed chemical form?

Established. The Foundayo label identifies orforglipron calcium, formula C48H47F2N10O5·0.5Ca and molecular mass 902.0 g/mol. Tablet strengths state milligrams of orforglipron, not milligrams of the calcium material. RCSB ligand V6G in structure 6XOX represents the parent compound, formula C48H48F2N10O5 and mass 882.956 Da. Keep the parent compound, calcium form, and stated tablet strength distinct when comparing chemical and trial records. Neither mass is a capsule-to-tablet dosing instruction.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§3,11; RCSB ligand V6G in PDB 6XOX; Kawai et al., PMID 33177239.

chemist-04 — What routes dominate disposition?

Established. The label describes oxidative metabolism primarily through CYP3A4; in vitro studies also identify CYP2J2 substrate activity. After a single radiolabeled dose, 87% of the dose was recovered in feces as metabolites; less than 1% was in urine. The reported terminal half-life is 29 to 49 hours, and protein binding exceeds 99%. Those values describe observed disposition under studied conditions. They do not locate one unique metabolic soft spot or prove that all exposure changes arise from a single enzyme.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.3.

chemist-05 — How do CYP3A4 interactions inform molecule assessment?

Established. The label study found carbamazepine reduced orforglipron AUC by 82%, while a strong CYP3A4 inhibitor raises exposure enough to trigger a 9 mg daily cap. Strong inhibitors that also inhibit OATP1B are avoided. These observations identify clinically important enzyme and transporter liabilities. They do not reveal a single chemical reaction center without metabolite characterization. A chemistry assessment should connect the radiolabel metabolite profile, enzyme studies, and transporter data before proposing structural modifications.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.2,7.1,12.3.

chemist-06 — Does high oral bioavailability prove a superior molecule?

Established. Foundayo has 77% absolute oral bioavailability at 0.8 mg in the label and can be taken with or without food. That is a meaningful formulation and exposure feature for this nonpeptide drug. It is not a direct ranking of weight efficacy, safety, or adherence versus an oral peptide product. Such outcomes depend on receptor pharmacology, dose, patient behavior, and study design. The current oral semaglutide product landscape also makes one older approximate absorption figure an unreliable class-wide comparator.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,12.3.

chemist-07 — Can beta-arrestin results guide a safer analog claim?

Uncertain. Sloop and colleagues report low intrinsic Gs efficacy and negligible beta-arrestin recruitment for orforglipron in their assays. A medicinal-chemistry hypothesis could ask whether pocket contacts tune those pathways, but bias estimates depend on assay amplification, receptor reserve, and reference ligand. The clinical meaning has not been established by the assay alone. A safer-analog claim would need exposure-matched in vivo and human comparisons with relevant adverse-event endpoints. State the assay conditions before extending the result.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1; Sloop et al., PMID 39693407; Kawai et al., PMID 33177239.

chemist-08 — Why cannot capsule milligrams be mapped directly to tablet milligrams?

Established. Ma and colleagues studied 429 otherwise healthy adults with overweight or obesity. They compared six capsule strengths with six corresponding tablet strengths after seven days of once-daily use under fasted study conditions. Prespecified exposure measures met bioequivalence criteria for those tested pairs; for example, a 36 mg research capsule corresponded to a 17.2 mg tablet. That measured bridge is not a general milligram-for-milligram substitution rule. The approved tablet label governs dispensing and dose decisions.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,3,14; Ma et al., tablet–capsule bioequivalence, PMID 41994902.

Investor / Diligence Analyst

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

analyst-01 — What are the patent and exclusivity dates and the current self-pay price?

Established. The FDA Orange Book lists patent RE50455 through September 26, 2037 and new chemical entity exclusivity through April 1, 2031 for Product 001. Lilly’s regular 30-day self-pay terms checked October 18, 2026 list $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 or 9 mg, and $349 for 14.5 or 17.2 mg. Temporary discounts have separate conditions. These listings do not predict generic entry, individual payment, or net revenue.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1; FDA Orange Book, NDA 220934 Product 001; Lilly Foundayo savings and coverage terms.

Editorial verification: [VERIFY: current patent and manufacturer terms before publication.]

analyst-02 — What is the mechanism-to-value proposition?

Established. Foundayo is an oral nonpeptide agonist of human GLP-1R, a target with established weight-management efficacy. The label permits once-daily administration with or without food, a practical differentiation from some oral peptide regimens. Label Trial 1 found −11.1% mean weight change at 17.2 mg versus −2.1% placebo at 72 weeks. That within-trial result validates product activity, not superiority to injectable or oral competitors. The diligence question is whether use, persistence, access, and cost translate the convenience feature into durable demand.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,2.1,12.1,14; ATTAIN-1, PMID 40960239.

analyst-03 — What does the indication cover today?

Established. The checked US label covers long-term weight reduction and maintenance in adults with obesity, or overweight plus at least one weight-related comorbidity, alongside diet and activity. Type 2 diabetes trials demonstrate glycemic effects, but do not create a separate diabetes indication in this label. ACHIEVE-4 reported cardiovascular safety noninferiority against insulin glargine, not an outcome-benefit indication. Revenue scenarios should separate approved use, studied populations, and potential future supplements.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,14; ACHIEVE-4, PMID 42815506.

Editorial verification: [VERIFY: current Drugs@FDA supplements before publication.]

analyst-04 — What do the ATTAIN studies say about addressable patients?

Established. Label Trial 1 enrolled 3,127 adults without type 2 diabetes, and Trial 2 enrolled 1,613 with type 2 diabetes. At 72 weeks, the 17.2 mg tablet-equivalent capsule dose showed mean weight changes of −11.1% versus −2.1% placebo in Trial 1 and −9.6% versus −2.5% in Trial 2. Those populations and results support a broad clinical evidence base within the adult weight-management indication. They are not market-size estimates. For addressable demand, check prevalence, eligibility, contraindications, payer coverage, prescriber access, and real-world persistence separately.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,14; ATTAIN-1, PMID 40960239; ATTAIN-2, PMID 41275875.

analyst-05 — What differentiates Foundayo from Wegovy pill and Zepbound?

Uncertain. Foundayo is an oral nonpeptide GLP-1R agonist with a with-or-without-food label. Wegovy pill is an oral peptide formulation with different administration rules, while Zepbound is an injectable dual GIP/GLP-1 agonist. Mechanism and route explain plausible convenience differences, but trial populations and estimands prevent a clean cross-trial efficacy ranking. The competitor-sponsored ORION indirect analysis is not a head-to-head randomized study. Check current labels, pricing, coverage, discontinuation, and persistence before choosing a commercial comparator.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,12.1,14; Novo Nordisk ORION indirect-comparison announcement, April 2, 2026.

Editorial verification: [VERIFY: current competing labels and access terms.]

analyst-06 — What are the important interaction liabilities for uptake?

Established. The label caps Foundayo at 9 mg daily with a strong CYP3A4 inhibitor, avoids strong inhibitors that also inhibit OATP1B, and avoids strong CYP3A4 inducers. It limits simvastatin to 20 mg daily and adds a 30-day non-oral or barrier contraception rule after starting and each escalation. These rules can complicate prescribing and counseling, even though dosing with or without food is simple. Quantify how often these co-medications occur in eligible patients before assigning a commercial impact.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.2,7.1–7.3.

analyst-07 — What does the regulatory history prove?

Established. FDA announced Foundayo approval on April 1, 2026 under its National Priority Voucher pilot. The approval establishes that FDA found the application met the regulatory standard for the labeled adult weight-management use. An accelerated review path is not a comparative efficacy endorsement, and approval timing alone says little about uptake. Recheck the current Drugs@FDA record for later supplements, labeling changes, and exclusivity records. Model launch, payer, and safety milestones as separate events.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1; FDA Drugs@FDA NDA 220934; FDA National Priority Voucher approval announcement, April 1, 2026.

Editorial verification: [VERIFY: regulatory status on publication date.]

analyst-08 — Which open checks matter most before an investment conclusion?

Uncertain. Start with the current label and Drugs@FDA record, then verify Orange Book patents and exclusivity, manufacturer price terms, payer coverage, prescription volumes, and persistence in claims data. Compare the labeled 72-week effect with direct rather than casual cross-trial competitor evidence. Ask whether the no-fasting routine improves actual continuation, and how gastrointestinal events or CYP3A4 interactions alter use. The sources cited here do not establish current net price, volume, or margin.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,2.1,7,14.

Editorial verification: [CITATION NEEDED: audited current utilization and net-price sources.]

General

Questions for this perspective

8 drafted questions in this packet. A perspective-specific question set.

general-01 — Who discovered orforglipron?

Established. Orforglipron began as a nonpeptide GLP-1 receptor program at Chugai in Japan. Chugai licensed the program to Eli Lilly in 2018. Lilly later developed Foundayo. This small molecule is taken by mouth. It activates the human GLP-1 receptor, which affects appetite and food intake. The licensing history explains the compound’s origin, while later clinical trials establish its effects in patients. It does not show that either company alone proved every subsequent result.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§11,12.1; Chugai licensing announcement, September 27, 2018.

Editorial verification: [VERIFY: current program rights.]

general-02 — How does one pill lead to weight loss?

Established. Foundayo contains orforglipron, which activates human GLP-1 receptors in appetite-related pathways. These signals help reduce food intake, while stomach emptying also slows, especially early in treatment. In a 72-week clinical trial, the top research capsule group lost 11.1% of starting weight on average, versus 2.1% with placebo. That capsule dose matches today’s 17.2 mg tablet. The group effect is not a personal forecast. A receptor diagram leaves out many biological steps between taking a pill and changing daily eating.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§12.1,12.2,14; ATTAIN-1, PMID 40960239.

general-03 — Is Foundayo an approved weight medicine?

Established. Yes. The checked US label covers adult weight reduction and long-term maintenance. It applies to obesity, or overweight with at least one health condition tied to weight. It is used with diet and activity changes. The prescription tablet is taken once daily with or without food. Research in diabetes does not by itself add a diabetes indication. The FDA application record dates the original approval to April 1, 2026. Check the current label when publishing because approved uses can change.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,2.1; FDA Drugs@FDA NDA 220934.

Editorial verification: [VERIFY: current approval scope.]

general-04 — Why is a pill possible when many GLP-1 drugs are shots?

Established. Orforglipron is a small nonpeptide molecule that can reach the blood after it is swallowed. The label reports 77% absolute bioavailability at one studied dose and allows it with or without food. Many familiar GLP-1 drugs are peptides with different delivery challenges. The useful lesson is that drugs aimed at one receptor can have very different forms and routines. It is not sound to infer from absorption alone that one works better or causes fewer side effects.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1,11,12.3.

general-05 — What is the biggest safety warning?

Established. Foundayo has a boxed warning about possible thyroid C-cell tumors. Other GLP-1 drugs that activate rodent receptors have caused these tumors in rodents. Orforglipron did not activate ordinary rat or mouse receptors and did not cause tumors in its rodent studies. The link to human risk is unknown. The label bars use in people with personal or family medullary thyroid cancer or MEN2, and with prior serious allergy to its ingredients. Ask a clinician to review such a history.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§Boxed Warning,4,5.1,13.1.

general-06 — What else should someone know before treatment?

Established. The label lists nausea, constipation, diarrhea, vomiting, and belly discomfort as common effects. Ongoing vomiting can drain body fluid and may injure the kidneys. Strong belly pain may need a check for pancreatitis. Foundayo can also change how some other drugs are handled, including certain cholesterol medicines and birth control pills. A pharmacist needs a complete list of drugs to check these rules. A short picture of the mechanism cannot show every safety issue in the official label.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§5.2–5.5,6.1,7.1–7.3.

general-07 — Does a trial result mean everyone loses weight?

Established. A clinical trial reports an average, which cannot predict one person’s response. In a 72-week randomized study of adults without type 2 diabetes, the top research capsule group lost 11.1% of starting weight on average. That dose matches today’s 17.2 mg tablet; the placebo group lost 2.1%. Some participants lost less, while others discontinued treatment because of adverse effects. Treatment also included food and activity changes. These results show a measurable group effect, not a guaranteed outcome for every individual.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§1,14; ATTAIN-1, PMID 40960239.

general-08 — Can it be taken with food?

Established. Yes. The Foundayo label allows one whole tablet each day, with or without food. This product-specific administration rule differs from the fasting routine for some other oral GLP-1 medicines. It does not make the drugs interchangeable, and their strengths do not correspond. The label also requires at least 30 days at each dose step before an increase is considered. A pharmacist can confirm the exact formulation and prescribed strength for someone who is uncertain about the routine.

Sources: Foundayo US Prescribing Information (DailyMed), revised July 2026 §§2.1; Rybelsus and Ozempic tablets US Prescribing Information, §2.1.